Liquidia Technologies, Inc.

Analyst Serge Belanger maintains a Buy rating on Liquidia Technologies (LQDA) with a $25 price target, optimistic about FDA approval for Yutrepia. Despite delays, legal barriers are cleared, anticipating significant market impact. Yutrepia's potential to challenge Tyvaso in PAH and PH-ILD treatment underpins this outlook, with approval expected by Q4 2024.

Serge Belanger of Needham maintains a Buy rating on Liquidia Technologies (LQDA) with a $19.00 target, citing Yutrepia's FDA approval potential by mid-2025 for PAH and PH-ILD treatments. Yutrepia's advantages include a superior inhaler, higher doses, better tolerance, and durability, positioning LQDA to benefit from a growing $2-4 billion market by 2030.

The Chronic Pulmonary Hypertension market is projected to grow significantly by 2034, driven by increased awareness, improved diagnostics, and emerging therapies. Key companies include Bayer, Attgeno AB, and others, with treatments like ADEMPAS and CS1. The US leads in market size and cases, with Germany and Japan following. Emerging therapies promise to revolutionize treatment dynamics.

The September 2024 Federal Circuit Update covers Supreme Court petitions, including Norwich Pharmaceuticals Inc. v. Salix Pharmaceuticals, Ltd., and recent Federal Circuit decisions on patent eligibility, indefiniteness, and expert qualifications in patent cases.

H.C. Wainwright maintains a Buy rating and $32.00 target for Liquidia Technologies, optimistic about Yutrepia's FDA approval for PAH and PH-ILD. Legal hurdles cleared, with Liquidia preparing for Yutrepia's market launch. Despite Q1 2024's $40.9M net loss, $157.9M cash reserves support commercialization efforts.